Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders

Annals of the New York Academy of Sciences

Volumn 1012, Issue , 2004, Pages 37-50

  Mattson, Mark P ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Alzheimer's disease; Apoptosis; Copper; Huntington's disease; Iron; Parkinson's disease

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; CALCIUM; CALCIUM CHELATING AGENT; CARRIER PROTEIN; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOSKELETON PROTEIN; ESTROGEN; HUNTINGTIN; IRON; IRON CHELATING AGENT; LIPID; MEMBRANE PROTEIN; METAL; NORDIHYDROGUAIARETIC ACID; OXYGEN RADICAL; POLYGLUTAMINE; REACTIVE OXYGEN METABOLITE; RECEPTOR; TOXIN; UBIDECARENONE; UBIQUITIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CALCIUM HOMEOSTASIS; CATALYSIS; CHELATION THERAPY; DEGENERATIVE DISEASE; DIET THERAPY; ENVIRONMENTAL FACTOR; GENE MUTATION; HEREDITY; HUMAN; HUNTINGTON CHOREA; IRON INTAKE; IRON STORAGE; LIPID PEROXIDATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROPHYLAXIS; PROTEIN DEGRADATION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA; GYMNOMYZA;

EID: 1842504355     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1306.004     Document Type: Review

References (101)

1. WISCHIK, C.M., C.R. HARRINGTON, E.B. MUKAETOVA-LADINSKA et al. 1992. Molecular characterization and measurement of Alzheimer's disease pathology: implications for genetic and environmental aetiology. Ciba Found. Symp. 169: 268-293.
2. LOTHARIUS, J. & P. BRUNDIN. 2002. Pathogenesis of Parkinson's disease: dopamine, vesicles, and alpha-synuclein. Nat. Rev. Neurosci. 3: 932-942.
3. REINER, A., R.L. ALBIN, K.D. ANDERSON et al. 1988. Differential loss of striatal projection neurons in Huntington's disease. Proc. Natl. Acad. Sci. USA 85: 5733-5737.
4. HAVERKAMP, L.I., V. APPEL & S.H. APPEL. 1995. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain 118: 707-719.
5. MATTSON, M.P., S.W. BARGER, B. CHENG et al. 1993. β-Amyloid precursor protein metabolites and loss of neuronal calcium homeostasis in Alzheimer's disease. Trends Neurosci. 16: 409-415.
6. MARK, R.J., E.M. BLANC & M.P. MATTSON. 1996. Amyloid β-peptide and oxidative cell injury in Alzheimer's disease. Mol. Neurobiol. 12: 211-224.
7. CHAN, S.L., K. FURUKAWA & M.P. MATTSON. 2002. Presenilins and APP in neuritic and synaptic plasticity: implications for the pathogenesis of Alzheimer's disease. Neuromol. Med. 2: 167-196.
8. JENNER, P. 2003. Oxidative stress in Parkinson's disease. Ann. Neurol. 53: S26-S36.
9. MATTSON, M.P., W.A. PEDERSEN, W. DUAN et al. 1999. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann. N.Y. Acad. Sci. 893: 154-175.
10. PETERSEN, A. & P. BRUNDIN. 2002. Huntington's disease: the mystery unfolds? Int. Rev. Neurobiol. 53: 315-339.
11. DIB, M. 2003. Amyotrophic lateral sclerosis: progress and prospects for treatment. Drugs 63: 289-310.
12. PEDERSEN, W.A., W. FU, J.N. KELLER et al. 1998. Protein modification by the lipid peroxidation product 4-hydroxynonenal in spinal cord tissue of ALS patients. Ann. Neurol. 44: 819-824.
13. YOUNG, A.B. 2003. Huntingtin in health and disease. J. Clin. Invest. 111: 299-302.
14. ROGAEVA, E. 2002. The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. Neuromol. Med. 2: 1-10.
15. COOKSON, M.R. 2003. Pathways to parkinsonism. Neuron 37: 7-10.
16. CUDKOWICZ, M.E., D. MCKENNA-YASEK, P.E. SAPP et al. 1997. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann. Neurol. 41: 210-221.
17. SMITH, J.D. 2000. Apolipoprotein E4: an allele associated with many diseases. Ann. Med. 32: 118-127.
18. BRUCE-KELLER, A.J., G. UMBERGER, R. MCFALL & M.P. MATTSON. 1999. Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann. Neurol. 45: 8-15.
19. DUAN, W. & M.P. MATTSON. 1999. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. Res. 57: 195-206.
20. ZHU, H., Q. GUO & M.P. MATTSON. 1999. Dietary restriction protects hippocampal neurons against the death-promoting action of a presenilin-1 mutation. Brain Res. 842: 224-229.
21. DUAN, W., Z. GUO, H. JIANG et al. 2003. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl. Acad. Sci. USA 100: 2911-2916.
22. PEDERSEN, W.A. & M.P. MATTSON. 1999. No benefit of dietary restriction on disease onset or progression in ALS Cu/Zn-SOD mutant mice. Brain Res. 833: 117-120.
23. KENNARD, M.L., H. FELDMAN, T. YAMADA & W.A. JEFFRIES. 1996. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat. Med. 2: 1230-1235.
24. LOGROSCINO, G., K. MARDER, J. GRAZIANO et al. 1997. Altered systemic iron metabolism in Parkinson's disease. Neurology 49: 714-717.
25. GOODMAN, Y. & M.P. MATTSON. 1994. Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Exp. Neurol. 128: 1-12.
26. YOUDIM, M.B., D. BEN-SHACHER & P. RIEDERER. 1993. The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8: 1-12.
27. MARKESBERY, W.R. & J.M. CARNEY. 1999. Oxidative alterations in Alzheimer's disease. Brain Pathol. 9: 133-146.
28. LOVELL, M.A., W.D. EHMANN, M.P. MATTSON & W.R. MARKESBERY. 1997. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol. Aging 18: 457-461.
29. CONNOR, J.R., S.L. MENZIES, S.M. ST. MARTIN et al. 1992. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J. Neurosci. Res. 31: 75-83.
30. LIM, G.P., T. CHU, F. YANG et al. 2001. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21: 8370-8377.
31. MATTSON, M.P., H. ZHU, J. YU & M.S. KINDY. 2000. Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo, and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis. J. Neurosci. 20: 1358-1364.
32. LAFONTAINE, M.A., M.P. MATTSON & D.A. BUTTERFIELD. 2002. Oxidative stress in synaptosomal proteins from mutant presenilin-1 knock-in mice: implications for familial Alzheimer's disease. Neurochem. Res. 27: 417-421.
33. BUTTERFIELD, D.A., K. HENSLEY, M. HARRIS et al. 1994. β-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem. Biophys. Res. Commun. 200: 710-715.
34. KELLER, J.N., R.J. MARK, A.J. BRUCE et al. 1997. 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience 80: 685-696.
35. MARK, R.J., M.A. LOVELL, W.R. MARKESBERY et al. 1997. A role for 4-hydroxynonenal in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J. Neurochem. 68: 255-264.
36. HENSLEY, K., J.M. CARNEY, M.P. MATTSON et al. 1994. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc. Natl. Acad. Sci. USA 91: 3270-3274.
37. HUANG, X., C.S. ATWOOD, M.A. HARTHSHOM et al. 1999. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616.
38. 2+ homeostasis and cell death. J. Neurosci. 15: 6239-6249.
39. MARK, R.J., Z. PANG, J.W. GEDDES et al. 1997. Amyloid β-peptide impairs glucose uptake in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. 17: 1046-1054.
40. q/11. J. Neurochem. 69: 570-580.
41. BLANC, E.M., J.N. KELLER, S. FERNANDEZ & M.P. MATTSON. 1998. 4-Hydroxynonenal, a lipid peroxidation product, inhibits glutamate transport in astrocytes. Glia 22: 149-160.
42. CUTLER, R.G., J. KELLEY, K. STORIE et al. 2004. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease, Proc. Natl. Acad. Sci. USA. In press.
43. DEXTER, D.T., F.R. WELLS, F. AGID et al. 1987. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2: 1219-1220.
44. SOFIC, E., P. RIEDERER, H. HEINSEN et al. 1988. Increased iron (III) and total iron content in postmortem substantia nigra of parkinsonian brain. J. Neural Transm. 74: 199-205.
45. GORELL, J.M., R.J. ORDIDGE, G.G. BROWN et al. 1995. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45: 1138-1143.
46. YORITAKA, A., N. HATTORI, K. UCHIDA et al. 1996. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA 93: 2696-2701.
47. BETARBET, R., T.B. SHERER, G. MACKENZIE et al. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3: 1301-1306.
48. SCHNEIDER, J.S., A. YUWILER & C.H. MARKHAM. 1987. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res. 411: 144-150.
49. DUAN, W., Z. ZHANG, D.M. GASH & M.P. MATTSON. 1999. Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann. Neurol. 46: 587-597.
50. DUAN, W., Z. ZHU, B. LADENHEIM et al. 2002. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol. 52: 597-606.
51. JENNER, P. & C.W. OLANOW. 1998. Understanding cell death in Parkinson's disease. Ann. Neurol. 44: S72-S84.
52. LEVENSON, C.W., W. DUAN, R.G. CUTLER et al. 2003. Dietary iron availability influences motor function and damage to dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem. Submitted.
53. PEREZ-SEVERIANO, F., C. RIOS & J. SEGOVIA. 2000. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. 862: 234-237.
54. BARTZOKIS, G., J. CUMMINGS, S. PERLMAN et al. 1999. Increased basal ganglia iron levels in Huntington disease. Arch. Neurol. 56: 569-574.
55. ANDREASSEN, O.A., A. DEDEOGLU, R.J. FERRANTE et al. 2001. Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8: 479-491.
56. KRETSCH, M.J., A.K. FONG, M.W. GREEN & H.L. JOHNSON. 1998. Cognitive function, iron status, and hemoglobin concentration in obese dieting women. Eur. J. Clin. Nutr. 52: 512-518.
57. GUO, Z., A. ERSOZ, D.A. BUTTERFIELD & M.P. MATTSON. 2000. Beneficial effects of dietary restriction on cerebral cortical synaptic terminals: preservation of glucose transport and mitochondria] function after exposure to amyloid β-peptide and oxidative and metabolic insults. J. Neurochem. 75: 314-320.
58. MATTSON, M.P. 2002. Accomplices to neuronal death. Nature 415: 377-379.
59. SMITH, R.G., Y.K. HENRY, M.P. MATTSON & S.H. APPEL. 1998. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann. Neurol. 44: 696-699.
60. PEDERSEN, W.A., S.L. CHAN & M.P. MATTSON. 2000. A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 74: 1426-1433.
61. PEDERSEN, W.A., N. CASHMAN & M.P. MATTSON. 1999. The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyl-transferase activity in NSC-19 motor neuron cells. Exp. Neurol. 155: 1-10.
62. GURNEY, M.E., F.B. CUTTING, P. ZHAI et al. 1996. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39: 147-157.
63. PEDERSEN, W.A., H. LUO, W. FU et al. 2000. Evidence that Par-4 participates in motor neuron death in amyotrophic lateral sclerosis. FASEB J. 14: 913-924.
64. WIEDAU-PAZOS, M., J.J. GOTO, S. RABIZADEH et al. 1996. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 271: 515-518.
65. KRUMAN, I.I., W.A. PEDERSEN, J.E. SPRINGER & M.P. MATTSON. 1999. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp. Neurol. 160: 28-39.
66. ROMAN, G.C. 1996. Neuroepidemiology of amyotrophic lateral sclerosis: clues to aetiology and pathogenesis. J. Neurol. Neurosurg. Psychiatry 61: 131-137.
67. CUTLER, R.G., W.A. PEDERSEN, S. CAMANDOLA et al. 2002. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in ALS. Ann. Neurol. 52: 448-457.
68. MATTSON, M.P. 2000. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 1: 120-129.
69. KELLER, J.N., M.S. KINDY, F.W. HOLTSBERG et al. 1998. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J. Neurosci. 18: 687-697.
70. YU, Z.F., A.J. BRUCE-KELLER, Y. GOODMAN & M.P. MATTSON. 1998. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J. Neurosci. Res. 53: 613-625.
71. SOROND, F.A. & R.R. RATAN. 2000. Ironing-out mechanisms of neuronal injury under hypoxic-ischemic conditions and potential role of iron chelators as neuroprotective agents. Antioxid. Redox Signal 2: 421-436.
72. DAVALOS, A., J. CASTILLO, J. MARRUGAT et al. 2000. Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology 54: 1568-1574.
73. PALMER, C., R.L. ROBERTS & C. BERO. 1994. Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats. Stroke 25: 1039-1045.
74. SEMPOS, C.T. & A.C. LOOKER. 1999. Iron status and the risk of coronary heart disease. Nutr. Metab. Cardiovasc. Dis. 9: 294-303.
75. GARIBALLA, S.E. 2000. Nutritional factors in stroke. Br. J. Nutr. 84: 5-17.
76. CHERNY, R.A., C.S. ATWOOD, M.E. XILINAS et al. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665-676.
77. YOUDIM, M.B., M. GASSEN, A. GROSS et al. 2000. Iron chelating, antioxidant, and cytoprotective properties of dopamine receptor agonist; apomorphine. J. Neural Transm. Suppl. 58: 83-96.
78. KAUR, D. et al. 2003. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909.
79. BUSH, A.I. 2003. The metallobiology of Alzheimer's disease. Trends Neurosci. 26: 207-214.
80. CRAPPER MCLACHLAN, D.R., A.J. DALTON, T.P. KRUCK et al. 1991. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337: 1304-1308.
81. HARA, H., H. KATO & K. KOGURE. 1990. Protective effect of alpha-tocopherol on ischemic neuronal damage in the gerbil hippocampus. Brain Res. 510: 335-338.
82. GOODMAN, Y., A.J. BRUCE, B. CHENG & M.P. MATTSON. 1996. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem. 66: 1836-1844.
83. +-ATPase activity, glucose transport, and glutamate transport induced by amyloid β-peptide and iron. J. Neurosci. Res. 50: 522-530.
84. GOODMAN, Y., M.R. STEINER, S.M. STEINER & M.P. MATTSON. 1994. Nordihydroguaiaretic acid protects hippocampal neurons against amyloid β-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res. 654: 171-176.
85. SHULTS, C.W., D. OAKES & K. KIEBURTZ. 2002. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59: 1541-1550.
86. PROLLA, T.A. & M.P. MATTSON. 2001. Molecular mechanisms of brain aging and neurodegenerative disorders: lessons from dietary restriction. Trends Neurosci. 24: S21-S31.
87. MATTSON, M.P., S.L. CHAN & W. DUAN. 2002. Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol. Rev. 82: 637-672.
88. YU, Z.F. & M.P. MATTSON. 1999. Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J. Neurosci. Res. 57: 830-839.
89. DUAN, W., Z. GUO & M.P. MATTSON. 2001. Brain-derived neurotrophic factor mediates an excitoprotective effect of dietary restriction in mice. J. Neurochem. 76: 619-626.
90. LEE, J., W. DUAN & M.P. MATTSON. 2002. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J. Neurochem. 82: 1367-1375.
91. i and neurotoxicity, and increase antioxidant enzyme activities in hippocampal neurons. J. Neurochem., 65: 1740-1751.
92. MATTSON, M.P. & T.B. SHEA. 2003. Folate and homocysteine metabolism in neural plasticity and neurodegeneratjve disorders. Trends Neurosci. 26: 137-146.
93. HO, P.I. et al. 2001. Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J. Neurochem. 78: 249-253.
94. KRUMAN, I., S.L. CHAN, C. CULMSEE et al. 2000. Homocysteine elicits a DNA damage response in neurons resulting in apoptosis and hypersensitivity to excitotoxicjty. J. Neurosci. 20: 6920-6926.
95. KRUMAN, I.I., T.S. KUMARAVEL, A. LOHANI et al. 2002. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J. Neurosci. 22: 1752-1762.
96. PAK, K., S.L. CHAN & M.P. MATTSON. 2003. Homocysteine and folate deficiency sensitize oligodendrocytes to the cell death-promoting effects of a presenilin-1 mutation and amyloid beta-peptide. Neuromol. Med. 3: 119-127.
97. LU, C., S.L. CHAN, N. HAUGHEY et al. 2001. Selective and biphasic effect of the membrane lipid peroxidation product 4-hydroxy-2,3-nonenal on N-methyl-D-aspartate channels. J. Neurochem. 78: 577-589.
98. 2+ channels in neurons by increasing protein tyrosine phosphorylation. J. Biol. Chem. 277: 24368-24375.
99. KELLER, J.N., K.B. HANNI, S.P. GABBITA et al. 1999. Oxidized lipoproteins increase reactive oxygen species formation in microglia and astrocyte cell lines. Brain Res. 830: 10-15.
100. KELLER, J.N., K.B. HANNI, W.A. PEDERSEN et al. 1999. Opposing actions of native and oxidized lipoprotein on motor neuron-like cells. Exp. Neurol. 157: 202-210.
101. MATTSON, M.P. 1998. Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. Trends Neurosci. 21: 53-57.